The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Affibody Molecules in Biotechnological and Medical Applications
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A small-molecule dye for NIR-II imaging
Antaris, A. L., Chen, H., Cheng, K., Sun, Y., Hong, G., Qu, C., Diao, S., Deng, Z., Hu, X., Zhang, B., et al. (2016) · Nature Materials · doi:10.1038/nmat4476 · Cited by 1,778
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain
Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M., & Nygren, P.-Å. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-772 · Cited by 662
Self-citationLöfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 651
Self-citationTumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation
Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S., & Härd, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711731105 · Cited by 410
Self-citationSchlapschy, M., Binder, U., Borger, C., Theobald, I., Wachinger, K., Kisling, S., Haller, D., & Skerra, A. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt023 · Cited by 342
Engineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
LOVTRAP: an optogenetic system for photoinduced protein dissociation
Wang, H., Vilela, M., Winkler, A., Tarnawski, M., Schlichting, I., Yumerefendi, H., Kuhlman, B., Liu, R., Danuser, G., & Hahn, K. M. (2016) · Nature Methods · doi:10.1038/nmeth.3926 · Cited by 311
Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073239 · Cited by 308
A combinatorial library of an α-helical bacterial receptor domain
Nord, K., Nilsson, J., Nilsson, B., Uhlén, M., & Nygren, P.-Å. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.6.601 · Cited by 285
Self-citationNygren, P. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06438.x · Cited by 282
Self-citationMeasuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT
Sörensen, J., Velikyan, I., Sandberg, D., Wennborg, A., Feldwisch, J., Tolmachev, V., Orlova, A., Sandström, M., Lubberink, M., Olofsson, H., et al. (2016) · Theranostics · doi:10.7150/thno.13502 · Cited by 264
Sörensen, J., Sandberg, D., Sandström, M., Wennborg, A., Feldwisch, J., Tolmachev, V., Åström, G., Lubberink, M., Garske-Román, U., Carlsson, J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131243 · Cited by 258
Engineering of a femtomolar affinity binding protein to human serum albumin
Jonsson, A., Dogan, J., Herne, N., Abrahmsen, L., & Nygren, P.-A. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn028 · Cited by 242
Self-citationAdvances in Anticancer Immunotoxin Therapy
Alewine, C., Hassan, R., & Pastan, I. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0358 · Cited by 188
Design of an Optimized Scaffold for Affibody Molecules
Feldwisch, J., Tolmachev, V., Lendel, C., Herne, N., Sjöberg, A., Larsson, B., Rosik, D., Lindqvist, E., Fant, G., Höidén-Guthenberg, I., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.002 · Cited by 181
Feng, G., Fang, Y., Liu, J., Geng, J., Ding, D., & Liu, B. (2017) · Small · doi:10.1002/smll.201602807 · Cited by 179
Yang, H., Cai, W., Xu, L., Lv, X., Qiao, Y., Li, P., Wu, H., Yang, Y., Zhang, L., & Duan, Y. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.013 · Cited by 178
Andersen, J. T., Pehrson, R., Tolmachev, V., Daba, M. B., Abrahmsén, L., & Ekblad, C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164848 · Cited by 177
Extension of in vivo half-life of biologically active molecules by XTEN protein polymers
Podust, V. N., Balan, S., Sim, B.-C., Coyle, M. P., Ernst, U., Peters, R. T., & Schellenberger, V. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.038 · Cited by 166
Non-immunoglobulin based protein scaffolds
Löfblom, J., Frejd, F. Y., & Ståhl, S. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.002 · Cited by 156
Self-citationYang, M., Cheng, K., Qi, S., Liu, H., Jiang, Y., Jiang, H., Li, J., Chen, K., Zhang, H., & Cheng, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.014 · Cited by 137
Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides
Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S., & Herne, N. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.09.013 · Cited by 127
Self-citationSequestration of a β‐Hairpin for Control of α‐Synuclein Aggregation
Mirecka, E. A., Shaykhalishahi, H., Gauhar, A., Akgül, Ş., Lecher, J., Willbold, D., Stoldt, M., & Hoyer, W. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309001 · Cited by 127
Nord, K., Nord, O., Uhlén, M., Kelley, B. D., Ljungqvist, C., & Nygren, P. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02344.x · Cited by 117
Self-citationBacterial display in combinatorial protein engineering
Löfblom, J. (2011) · Biotechnology Journal · doi:10.1002/biot.201100129 · Cited by 112
Self-citationSandström, M., Lindskog, K., Velikyan, I., Wennborg, A., Feldwisch, J., Sandberg, D., Максимилианович, Т. В., Orlova, A., Sørensen, J., Carlsson, J., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.169342 · Cited by 110
Immunogenicity of therapeutic recombinant immunotoxins
Mazor, R., Onda, M., & Pastan, I. H. (2016) · Immunological Reviews · doi:10.1111/imr.12390 · Cited by 110
Tolmachev, V., Stone‐Elander, S., & Orlova, A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70088-7 · Cited by 95
Lu, N., Tian, Y., Tian, W., Huang, P., Liu, Y., Tang, Y., Wang, C., Wang, S., Su, Y., Zhang, Y., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b09585 · Cited by 95
Wållberg, H., Orlova, A., Altai, M., Hosseinimehr, S. J., Widström, C., Malmberg, J., Ståhl, S., & Максимилианович, Т. В. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.083592 · Cited by 94
Self-citationSamkoe, K. S., Gunn, J. R., Marra, K. A., Hull, S. M., Moodie, K. L., Feldwisch, J., Strong, T. V., Draney, D. R., Hoopes, P. J., Roberts, D. W., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1033-y · Cited by 90
Lindborg, M., Cortez, E., Höidén‐Guthenberg, I., Gunneriusson, E., von Hage, E., Syud, F. A., Morrison, M., Abrahmsén, L., Herne, N., Pietras, K., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.033 · Cited by 89
Self-citationHansson, M., Ringdahl, J., Robert, A., Power, U. F., Goetsch, L., Nguyen, T. N., Uhlén, M., Ståhl, S., & Nygren, P. (1999) · Immunotechnology · doi:10.1016/s1380-2933(98)00026-8 · Cited by 85
Self-citationDelivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen
Liao, X., Rabideau, A. E., & Pentelute, B. L. (2014) · ChemBioChem · doi:10.1002/cbic.201402290 · Cited by 83
Anti‐idiotypic protein domains selected from protein A‐based affibody libraries
Eklund, M., Axelsson, L., Uhlén, M., & Nygren, P. (2002) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10169 · Cited by 83
Self-citationKronqvist, N., Malm, M., Göstring, L., Gunneriusson, E., Nilsson, M., Höidén‐Guthenberg, I., Gedda, L., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq118 · Cited by 81
Self-citationSequestration of the Aβ Peptide Prevents Toxicity and Promotes Degradation In Vivo
Luheshi, L. M., Hoyer, W., de Barros, T. P., Härd, I. V. D., Brorsson, A., Macao, B., Persson, C., Crowther, D. C., Lomas, D. A., Ståhl, S., et al. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000334 · Cited by 79
Self-citationAffibody Scaffolds Improve Sesquiterpene Production in Saccharomyces cerevisiae
Tippmann, S., Anfelt, J., David, F., Rand, J. M., Siewers, V., Uhlén, M., Nielsen, J., & Hudson, E. P. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00109 · Cited by 77
Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors
Pieve, C. D., Allott, L., Martins, C. D., Vardon, A., Ciobota, D. M., Krämer-Marek, G., & Smith, G. S. T. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00259 · Cited by 75
Zieliński, R., Lyakhov, I. G., Jacobs, A., Chertov, O., Krämer-Marek, G., Francella, N., Stephen, A. G., Fisher, R. J., Blumenthal, R. P., & Capala, J. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ad4d5d · Cited by 72
Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L., Bass, T. Z., Frejd, F. Y., Höidén‐Guthenberg, I., Varasteh, Z., Orlova, A., Максимилианович, Т. В., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062791 · Cited by 72
Self-citationFeasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
Honarvar, H., Westerlund, K., Altai, M., Sandström, M., Orlova, A., Максимилианович, Т. В., & Karlström, A. E. (2015) · Theranostics · doi:10.7150/thno.12766 · Cited by 68
Affibody-mediated PET imaging of HER3 expression in malignant tumours
Rosestedt, M., Andersson, K. G., Mitran, B., Максимилианович, Т. В., Löfblom, J., Orlova, A., & Ståhl, S. (2015) · Scientific Reports · doi:10.1038/srep15226 · Cited by 67
Self-citationFluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody
Sexton, K. J., Tichauer, K. M., Samkoe, K. S., Gunn, J. R., Hoopes, P. J., & Pogue, B. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060390 · Cited by 66
Hofström, C., Altai, M., Honarvar, H., Strand, J., Malmberg, J., Hosseinimehr, S. J., Orlova, A., Gräslund, T., & Максимилианович, Т. В. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400218y · Cited by 66
Self-citationTargeting HER2‐positive cancer cells with receptor‐redirected anthrax protective antigen
McCluskey, A. J., Olive, A. J., Starnbach, M. N., & Collier, R. J. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.12.003 · Cited by 66
Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting
Altai, M., Perols, A., Tsourma, M., Mitran, B., Honarvar, H., Robillard, M. S., Rossin, R., ten Hoeve, W., Lubberink, M., Orlova, A., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162248 · Cited by 62
Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRβ Expression in Vivo
Strand, J., Varasteh, Z., Eriksson, O., Abrahmsén, L., Orlova, A., & Максимилианович, Т. В. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500284t · Cited by 61
Tolmachev, V., Mume, E., Sjöberg, S., Frejd, F., & Orlova, A. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-1003-y · Cited by 61
Self-citationGarousi, J., ANDERSSON, K. G., Mitran, B., PICHL, M.-L., Ståhl, S., Orlova, A., Löfblom, J., & Максимилианович, Т. В. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3369 · Cited by 59
Self-citationvan Scheltinga, A. G. T. T., Hooge, M. N. L., Abiraj, K., Schröder, C. P., Pot, L., Bossenmaier, B., Thomas, M., Hölzlwimmer, G., Friess, T., Kosterink, J. G. W., et al. (2014) · mAbs · doi:10.4161/mabs.29097 · Cited by 55
Seijsing, J., Lindborg, M., Höidén‐Guthenberg, I., Bönisch, H., Gunneriusson, E., Frejd, F. Y., Abrahmsén, L., Ekblad, C., Löfblom, J., Uhlén, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417717111 · Cited by 54
Self-citationBeuttler, J., Rothdiener, M., Müller, D., Frejd, F. Y., & Kontermann, R. E. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900061v · Cited by 53
Self-citationMalm, M., Bass, T. Z., Gudmundsdotter, L., Lord, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2014) · Biotechnology Journal · doi:10.1002/biot.201400009 · Cited by 52
Self-citationTargeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Malm, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2016) · mAbs · doi:10.1080/19420862.2016.1212147 · Cited by 52
Self-citationHER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
Zieliński, R., Lyakhov, I. G., Hassan, M., Kuban, M., Shafer-Weaver, K., Gandjbakhche, A., & Capala, J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2887 · Cited by 51
Alavizadeh, S. H., Akhtari, J., Badiee, A., Golmohammadzadeh, S., & Jaafari, M. R. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1121987 · Cited by 51
LaFleur, D. W., Abramyan, D., Kanakaraj, P., Smith, R. G., Shah, R. R., Wang, G., Yao, X.-T., Kankanala, S., Boyd, E., Zaritskaya, L., et al. (2013) · mAbs · doi:10.4161/mabs.23043 · Cited by 50
Affibody‐mediated transferrin depletion for proteomics applications
Grönwall, C., Sjöberg, A., Ramström, M., Höidén‐Guthenberg, I., Hober, S., Jonasson, P., & Ståhl, S. (2007) · Biotechnology Journal · doi:10.1002/biot.200700053 · Cited by 50
Self-citationβ-Hairpin of Islet Amyloid Polypeptide Bound to an Aggregation Inhibitor
Mirecka, E. A., Feuerstein, S., Gremer, L., Schroeder, G. F., Stoldt, M., Willbold, D., & Hoyer, W. (2016) · Scientific Reports · doi:10.1038/srep33474 · Cited by 49
Westerlund, K., Honarvar, H., Norrström, E., Strand, J., Mitran, B., Orlova, A., Karlström, A. E., & Максимилианович, Т. В. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00089 · Cited by 47
Woldring, D., Holec, P. V., Stern, L. A., Du, Y., & Hackel, B. J. (2017) · Biochemistry · doi:10.1021/acs.biochem.6b01142 · Cited by 47
Fleetwood, F., Klint, S., Hanze, M., Gunneriusson, E., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2014) · Scientific Reports · doi:10.1038/srep07518 · Cited by 46
Self-citationPerols, A., Honarvar, H., Strand, J., Selvaraju, R., Orlova, A., Karlström, A. E., & Максимилианович, Т. В. (2012) · Bioconjugate Chemistry · doi:10.1021/bc3002369 · Cited by 44
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Guo, R., Guo, W., Cao, L., Liu, H., Liu, J., Xu, H., Huang, W., Wang, F., & Hong, Z. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.07.046 · Cited by 44
Garousi, J., Honarvar, H., Andersson, K. G., Mitran, B., Orlova, A., Buijs, J., Löfblom, J., Frejd, F. Y., & Максимилианович, Т. В. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00502 · Cited by 44
Self-citationElliott, J. T., Marra, K. A., Evans, L. T., Davis, S. C., Samkoe, K. S., Feldwisch, J., Paulsen, K. D., Roberts, D. W., & Pogue, B. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1400 · Cited by 44
Li, J., Lundberg, E. K., Vernet, E., Larsson, B., Höidén‐Guthenberg, I., & Gräslund, T. (2010) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090226 · Cited by 43
Self-citationGujrati, V., Lee, M., Ko, Y., Lee, S. E., Kim, D., Kim, H., Kang, S., Lee, S., Kim, J., Jeon, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509371113 · Cited by 43
de Souza, A. L. R., Marra, K. A., Gunn, J. R., Samkoe, K. S., Hoopes, P. J., Feldwisch, J., Paulsen, K. D., & Pogue, B. W. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0980-7 · Cited by 42
Berlec, A., Perše, M., Ravnikar, M., Lunder, M., Erman, A., Cerar, A., & Štrukelj, B. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.12.027 · Cited by 42
Lindberg, H., Härd, T., Löfblom, J., & Ståhl, S. (2015) · Biotechnology Journal · doi:10.1002/biot.201500131 · Cited by 39
Self-citationWesterlund, K., Honarvar, H., Максимилианович, Т. В., & Karlström, A. E. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00292 · Cited by 38
Generation of affibody molecules specific for HPV16 E7 recognition
Xue, X., Wang, B., Du, W., Zhang, C., Song, Y., Cai, Y., Cen, D., Wang, L., Xiong, Y., Jiang, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12174 · Cited by 38
Receptor-Directed Chimeric Toxins Created by Sortase-Mediated Protein Fusion
McCluskey, A. J., & Collier, R. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0358 · Cited by 36
Wållberg, H., Grafström, J., Cheng, Q., Lu, L., Ahlzén, H.-S. M., Samén, E., Thorell, J.-O., Johansson, K., Dunås, F., Olofsson, M. H., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.102194 · Cited by 35
Self-citationSochaj-Gregorczyk, A. M., Serwotka-Suszczak, A. M., & Otlewski, J. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000125 · Cited by 35
Selection and characterization of an HIV‐1 gp120‐binding affibody ligand
Wikman, M., Rowcliffe, E., Friedman, M., Henning, P., Lindholm, L., Olofsson, S., & Ståhl, S. (2006) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20060016 · Cited by 34
Self-citationAndersson, K. G., Oroujeni, M., Garousi, J., Mitran, B., Ståhl, S., Orlova, A., Löfblom, J., & Максимилианович, Т. В. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3721 · Cited by 34
Self-citationAmreddy, N., Vijayashree, K., Irudayaraj, J., Manorama, S. V., & Rao, N. M. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.063 · Cited by 33
Hagen, S. H., Baumann, T., Wagner, H. J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K. M., & Müller, K. M. (2014) · Scientific Reports · doi:10.1038/srep03759 · Cited by 32
A GLP‐1 receptor agonist conjugated to an albumin‐binding domain for extended half‐life
Lindgren, J., Refai, E., Zaitsev, S. V., Abrahmsén, L., Berggren, P., & Karlström, A. E. (2014) · Biopolymers · doi:10.1002/bip.22474 · Cited by 32
Gottlieb, A. B., Blauvelt, A., Prinz, J. C., Papanastasiou, P., Pathan, R. B., Nyirady, J., Fox, T., & Papavassilis, C. (2016) · PubMed · Cited by 32
Mirecka, E. A., Gremer, L., Schiefer, S., Oesterhelt, F., Stoldt, M., Willbold, D., & Hoyer, W. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.06.006 · Cited by 29
Analytical applications of affibodies
Justino, C. I. L., Duarte, A. C., & Rocha‐Santos, T. (2014) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2014.10.014 · Cited by 29
Altai, M., Liu, H., Orlova, A., Максимилианович, Т. В., & Gräslund, T. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3614 · Cited by 28
Self-citationEngineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo
Suffian, I. F. M., Wang, J. T.-W., Hodgins, N. O., Klippstein, R., Garcia‐Maya, M., Brown, P. R., Nishimura, Y., Heidari, H., Bals, S., Sosabowski, J. K., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.12.012 · Cited by 28
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells
Schardt, J. S., Oubaid, J. M., Williams, S. C., Howard, J. L., Aloimonos, C. M., Bookstaver, M. L., Lamichhane, T. N., Sokic, S., Liyasova, M., O’Neill, M. J., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00919 · Cited by 28
Half‐Life Extension by Binding to Albumin through an Albumin Binding Domain
Frejd, F. Y. (2012) · Wiley eBooks · doi:10.1002/9783527644827.ch14 · Cited by 27
Self-citationYu, F., Gudmundsdotter, L., Akal, A., Gunneriusson, E., Frejd, F. Y., & Nygren, P. (2014) · mAbs · doi:10.4161/mabs.36089 · Cited by 27
Self-citationAlternative Conformations of the Tau Repeat Domain in Complex with an Engineered Binding Protein
Grüning, C. S. R., Mirecka, E. A., Klein, A. N., Mandelkow�, E., Willbold, D., Marino, S. F., Stoldt, M., & Hoyer, W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.560920 · Cited by 27
Mitran, B., Altai, M., Hofström, C., Honarvar, H., Sandström, M., Orlova, A., Максимилианович, Т. В., & Gräslund, T. (2014) · Amino Acids · doi:10.1007/s00726-014-1859-z · Cited by 25
Self-citationKhaw, B., Gada, K. S., Patil, V., Panwar, R., Mandapati, S., Hatefi, A., Majewski, S., & Weisenberger, A. G. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2738-2 · Cited by 24
LIU, H., Seijsing, J., Frejd, F. Y., Максимилианович, Т. В., & Gräslund, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3027 · Cited by 24
Self-citationSelection and characterization of Affibody® ligands to the transcription factor c‐Jun
Lundberg, E. K., Brismar, H., & Gräslund, T. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20070178 · Cited by 24
Self-citationA Native Chemical Ligation Approach for Combinatorial Assembly of Affibody Molecules
Lindgren, J., Ekblad, C., Abrahmsén, L., & Karlström, A. E. (2012) · ChemBioChem · doi:10.1002/cbic.201200052 · Cited by 24
Dong, D., Xia, G., Li, Z., & Li, Z. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00265 · Cited by 24
Generation of Affibody® ligands binding interleukin‐2 receptor α/CD25
Grönwall, C., Snelders, E., Palm, A. J., Eriksson, F., Herne, N., & Ståhl, S. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20070261 · Cited by 23
Self-citationVelikyan, I., Wennborg, A., Feldwisch, J., Lindman, H., Carlsson, J., & Sørensen, J. C. H. (2016) · PubMed Central · Cited by 23
Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling
Fleetwood, F., Güler, R., Gordon, E. J., Ståhl, S., Claesson, L., & Löfblom, J. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2088-7 · Cited by 22
Self-citationBass, T. Z., Rosestedt, M., Mitran, B., Frejd, F. Y., Löfblom, J., Максимилианович, Т. В., Ståhl, S., & Orlova, A. (2017) · Scientific Reports · doi:10.1038/srep43118 · Cited by 19
Self-citationDesign and evaluation of radiolabeled tracers for tumor imaging
Wållberg, H., & Ståhl, S. (2013) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1111 · Cited by 18
Self-citationA Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
Serwotka-Suszczak, A. M., Sochaj-Gregorczyk, A. M., Pieczykolan, J., Krowarsch, D., Jeleń, F., & Otlewski, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020401 · Cited by 18
Dar, G. H., Gopal, V., & Rao, M. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.01.017 · Cited by 16
Sel-tag imaging project, Cheng, Q., Wållberg, H., Grafström, J., Lu, L., Thorell, J.-O., Olofsson, M. H., Linder, S. T., Johansson, K., Tegnebratt, T., et al. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0213-8 · Cited by 16
Self-citationOptimization of Liganded Polyethylenimine Polyethylene Glycol Vector for Nucleic Acid Delivery
Joubran, S., Zigler, M., Pessah, N., Klein, S., Shir, A., Edinger, N., Sagalov, A., Razvag, Y., Reches, M., & Levitzki, A. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500252a · Cited by 15
Inhibitory effects of H-Ras/Raf-1-binding affibody molecules on synovial cell function
Shibasaki, S., Karasaki, M., Gräslund, T., Nygren, P., Sano, H., & Iwasaki, T. (2014) · AMB Express · doi:10.1186/s13568-014-0082-3 · Cited by 15
Self-citationPogue, B. W., Paulsen, K. D., Samkoe, K. S., Elliott, J. T., Hasan, T. G., Strong, T. V., Draney, D. R., & Feldwisch, J. (2016) · Medical Physics · doi:10.1118/1.4951732 · Cited by 12
The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption
Berglund, M. M., & Strömberg, P. (2016) · Expert Review of Proteomics · doi:10.1586/14789450.2016.1148604 · Cited by 9
Choi, J.-W., Hong, S. T., Kang, D. E., Paik, K. C., Han, M. S., Lim, C. S., & Cho, B. R. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b00912 · Cited by 9
Impact of subunit linkages in an engineered homodimeric binding protein to -synuclein
Gauhar, A., Shaykhalishahi, H., Gremer, L., Mirecka, E. A., & Hoyer, W. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu047 · Cited by 7
Genst, E. D., & Muyldermans, S. (2015) · Biotechnology Journal · doi:10.1002/biot.201500405 · Cited by 6
Bhattarai, P. R., Vance, D., Hatefi, A., & Khaw, B. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1271421 · Cited by 5
Lindberg, H., Sandersjöö, L., Meister, S. W., Uhlén, M., Löfblom, J., & Ståhl, S. (2016) · Biotechnology Journal · doi:10.1002/biot.201600364 · Cited by 3
Self-citation
Cited by
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Extracellular HMGB1 as a therapeutic target in inflammatory diseases
Andersson, U., Yang, H., & Harris, H. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1439924 · Cited by 287
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
Gohil, S. H., Iorgulescu, J. B., Braun, D. A., Keskin, D. B., & Livak, K. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00449-x · Cited by 282
Metadata
- Authors
- Ståhl, S., Gräslund, T., Eriksson Karlström, A., Frejd, F. Y., Nygren, P.-Å., & Löfblom, J.
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 35
- Issue
- 8
- Pages
- 691-712
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W2613618878
- Cited by
- 382
- References
- 116
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.